Company

Solasia Pharma K.K.

Headquarters: Tokyo, Japan

Employees: 77

CEO: Mr. Yoshihiro Arai

JPX: 4597

Market Cap

¥5.99 Billion

JPY as of July 1, 2024

US$37.1 Million

Market Cap History

Solasia Pharma K.K. market capitalization over time

Evolution of Solasia Pharma K.K. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Solasia Pharma K.K.

Detailed Description

Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Solasia Pharma K.K. has the following listings and related stock indices.


Stock: JPX: 4597 wb_incandescent

Stock: FSX: 9SO wb_incandescent

Details

Headquarters:

Sumitomo Fudosan Shiba-Koen Tower

4th Floor 2-11-1, Shiba-koen Minato-ku

Tokyo, 105-0011

Japan

Phone: 81 3 5843 8045